Evidence map›Paper›PMID 42590956›Full record

ArticlePediatric transplantation2026

Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation.

H Pizzo, A Barbera, K Westreich, M E Seifert, J Mirocha, K Kirshner, D Puliyanda

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

H PizzoPediatric Nephrology, Cedars-Sinai Guerin Children's, Los Angeles, USA.ORCID https://orcid.org/0000-0003-2997-7483
A BarberaPediatric Nephrology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, USA.ORCID https://orcid.org/0009-0006-0137-2916
K WestreichPediatric Nephrology, University of North Carolina, Chapel Hill, USA.ORCID https://orcid.org/0009-0002-7208-2378
M E SeifertPediatric Nephrology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, USA.ORCID https://orcid.org/0000-0002-0557-6178
J MirochaBiostatistics Core, Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA.ORCID https://orcid.org/0000-0002-2338-193X
K KirshnerPediatric Nephrology, Cedars-Sinai Guerin Children's, Los Angeles, USA.
D PuliyandaPediatric Nephrology, Cedars-Sinai Guerin Children's, Los Angeles, USA.ORCID https://orcid.org/0000-0002-6988-8533

Funding

LL Foundation for Youth 300777
6 · The paper itself

Abstract

backgroundAlemtuzumab is an induction immunosuppressive agent effective in preventing hyperacute rejection; however, it can result in prolonged lymphocyte depletion. Here we assessed the dosing, tolerability, and outcomes with alemtuzumab induction via IV vs. SQ route in pediatric kidney transplantation.

methodsA multicenter analysis of 119 patients < 21 years old who received alemtuzumab induction immunosuppression. Total dose (mg) and dose by body weight (mg/kg) were assessed. Tolerability was defined by the development of leukopenia (WBC < 3.0 × 10

resultsA total of 83 and 36 recipients received alemtuzumab IV and SQ, respectively. SQ group was slightly older, 14.0 y. (SD 5.5) vs. 11.9 y. (SD 6.1) (p = 0.07), and had more highly sensitized recipients, 14 (38.9%) vs. 10 (12.1%) (p = 0.002). Total dose and dose by weight were higher in the SQ group, 22.3 mg (SD 8.9) vs. 14.9 mg (SD 9.5), and 0.57 mg/kg (SD 0.21) vs. 0.36 mg/kg (SD 0.18 mg), respectively (p = 0.0001 and p < 0.0001). SQ group experienced more leukopenia and resultant medication dose reduction; however, there were no differences between the groups in eGFR, infections, hospitalizations, and rejection in the year following transplant.

conclusionDespite the higher dose of alemtuzumab and rates of leukopenia in the SQ group, there were no other differences in tolerability and outcomes compared to IV alemtuzumab. Overall, alemtuzumab is well tolerated during the first year post-transplant as an induction immunosuppression agent in the pediatric population.

Indexed as

AlemtuzumabGraft RejectionImmunosuppressive AgentsKidney TransplantationAdministration, IntravenousAdolescentChildChild, PreschoolFemaleGraft SurvivalHumansInjections, SubcutaneousLeukopeniaMaleRetrospective StudiesTreatment OutcomeAlemtuzumabImmunosuppressive Agentsimmunosuppressioninductionoutcomespediatric

Identifiers

PMID42590956
PMCPMC13469996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.